Substrate recognition by the 4-hydroxytryptamine kinase PsiK in psilocybin biosynthesis.
Study Goal
The researchers aimed to analyze the structure and function of PsiK, an enzyme involved in psilocybin biosynthesis, to support future bioengineering efforts for enhanced therapeutic properties.
Results Summary
The study provided crystallographic and mutagenesis insights into PsiK's substrate recognition, which will aid in bioengineering psilocybin variants with improved therapeutic potential.
Population
Not specified (in vitro study)
Effective Dosage
Not mentioned
Duration
Not mentioned
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
Psilocybin | neutral | depression and several other mental health conditions | - | - | is a highly promising drug candidate for the treatment | #1 |
Psilocybin, the natural hallucinogen from Psilocybe (magic) mushrooms, is a highly promising drug candidate for the treatment of depression and several other mental health conditions. Biosynthesis of psilocybin from the amino acid l-tryptophan involves four strictly sequential modifications. The third of these, ATP-dependent phosphorylation of the intermediate 4-hydroxytryptamine, is catalysed by PsiK. Here we present a crystallographic analysis and a structure-based mutagenesis study of this kinase, providing insight into its mode of substrate recognition. The results of our work will support future bioengineering efforts aimed at generating variants of psilocybin with enhanced therapeutic properties.